Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06745323 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
A Phase 2 study of Small Cell Lung Cancer (SCLC), sponsored by Amgen.
- Active
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
- 20
- Study locations
NCT06745323 is a Phase 2 study of Small Cell Lung Cancer (SCLC) that is active but no longer recruiting, run by Amgen. The registered enrollment target is 252 participants, below the 337-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06745323, a Phase 2 study of Small Cell Lung Cancer (SCLC), is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).
Conditions Studied
Interventions
- DRUG Tarlatamab
Study Locations (20)
Other
- Grand Hopital de Charleroi - Site des Viviers - Charleroi
- Universitair Ziekenhuis Antwerpen - Edegem
- Jessa Ziekenhuis - Campus Virga Jesse - Hasselt
North Carolina
- Duke University - Durham
- FirstHealth Cancer Center - Pinehurst
Tennessee
- Tennessee Oncology PLLC - Chattanooga - Chattanooga
- Tennessee Oncology, PLLC - Nashville
Buenos Aires
- Fundacion Respirar - Ciudad Autonoma de Buenos Aires
- Instituto de Investigaciones clinicas de Mar del Plata - Mar del Plata
Victoria
- Monash Medical Centre - Clayton
- Austin Health, Austin Hospital - Heidelberg
California
- University of California Los Angeles - Los Angeles
Connecticut
- Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut - Plainville
Florida
- AdventHealth Hematology and Oncology - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2029-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06745323
The ClinicalTrials.gov registry entry for NCT06745323 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 337-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (25% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 1 intervention - of which Tarlatamab is the first listed.
NCT06745323 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, North Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06745323 about?
NCT06745323 is a clinical study titled "A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC". The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).
What is the current status of trial NCT06745323?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2025-02-26. Estimated completion is 2029-02-09.
What conditions does trial NCT06745323 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC).
What interventions are being tested in trial NCT06745323?
The interventions under investigation include: Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT06745323?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06745323 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
RECRUITING · Phase 2
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.